Latest Insider Transactions at Agios Pharmaceuticals, Inc. (AGIO)
This section provides a real-time view of insider transactions for Agios Pharmaceuticals, Inc. (AGIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AGIOS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AGIOS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2022
|
Jonathan Biller Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,523
+24.95%
|
-
|
|
Feb 18
2022
|
Bruce Car Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,874
+26.78%
|
-
|
|
Feb 18
2022
|
Richa Poddar Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,884
+29.4%
|
-
|
|
Feb 18
2022
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,271
+27.27%
|
-
|
|
Feb 16
2022
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
233
-8.38%
|
$6,990
$30.81 P/Share
|
|
Feb 14
2022
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
504
-15.34%
|
$15,624
$31.25 P/Share
|
|
Feb 14
2022
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
127
-3.72%
|
$3,810
$30.5 P/Share
|
|
Feb 14
2022
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
360
+9.54%
|
-
|
|
Feb 14
2022
|
Richa Poddar Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
590
-18.26%
|
$17,700
$30.5 P/Share
|
|
Feb 14
2022
|
Richa Poddar Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,738
+34.98%
|
-
|
|
Feb 14
2022
|
James William Burns Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,155
-13.11%
|
$64,650
$30.5 P/Share
|
|
Feb 14
2022
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,988
+18.83%
|
-
|
|
Feb 14
2022
|
Jacqualyn A Fouse Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,505
-5.03%
|
$105,150
$30.5 P/Share
|
|
Feb 14
2022
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,334
+13.99%
|
-
|
|
Feb 10
2022
|
Richa Poddar Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
725
-32.69%
|
$22,475
$31.43 P/Share
|
|
Feb 10
2022
|
Richa Poddar Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,068
+48.25%
|
-
|
|
Feb 10
2022
|
James William Burns Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
643
-6.37%
|
$19,933
$31.43 P/Share
|
|
Feb 10
2022
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,833
+15.37%
|
-
|
|
Feb 10
2022
|
Bruce Car Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,073
-8.26%
|
$33,263
$31.43 P/Share
|
|
Feb 10
2022
|
Bruce Car Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+22.01%
|
-
|
|
Feb 10
2022
|
Jonathan Biller Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,349
-7.3%
|
$41,819
$31.43 P/Share
|
|
Feb 10
2022
|
Jonathan Biller Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+16.57%
|
-
|
|
Feb 10
2022
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-8.29%
|
$8,463
$31.43 P/Share
|
|
Feb 10
2022
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
777
+19.1%
|
-
|
|
Feb 10
2022
|
Sarah Gheuens Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
758
-12.21%
|
$23,498
$31.43 P/Share
|
|
Feb 10
2022
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,162
+25.82%
|
-
|
|
Jan 06
2022
|
Bruce Car Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,205
-11.44%
|
$38,560
$32.58 P/Share
|
|
Jan 06
2022
|
Bruce Car Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,437
+24.61%
|
-
|
|
Dec 03
2021
|
Jonathan Biller Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,823
-10.97%
|
$63,805
$35.88 P/Share
|
|
Dec 03
2021
|
Jonathan Biller Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,753
+25.71%
|
-
|
|
Dec 02
2021
|
Sarah Gheuens Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
248
-5.77%
|
$8,680
$35.0 P/Share
|
|
Dec 02
2021
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
834
+16.26%
|
-
|
|
Jun 21
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,777
-100.0%
|
$108,397
$61.61 P/Share
|
|
Jun 21
2021
|
Carman Alenson Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,777
+50.0%
|
$90,627
$51.51 P/Share
|
|
Jun 18
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
48,493
-75.79%
|
$2,909,580
$60.11 P/Share
|
|
Jun 18
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
48,493
+25.97%
|
$2,182,185
$45.08 P/Share
|
|
Jun 17
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,502
-13.91%
|
$150,120
$60.02 P/Share
|
|
Jun 17
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,502
+12.21%
|
$97,578
$39.76 P/Share
|
|
Jun 10
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,853
-57.38%
|
$1,251,180
$60.06 P/Share
|
|
Jun 10
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,853
+36.46%
|
$813,267
$39.76 P/Share
|
|
Jun 09
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,149
-31.58%
|
$428,940
$60.16 P/Share
|
|
Jun 09
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,149
+24.0%
|
$278,811
$39.76 P/Share
|
|
Jun 08
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,675
-30.12%
|
$400,500
$60.07 P/Share
|
|
Jun 08
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,675
+23.15%
|
$260,325
$39.76 P/Share
|
|
Jun 07
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,268
-21.6%
|
$256,080
$60.04 P/Share
|
|
Jun 07
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,268
+17.77%
|
$166,452
$39.76 P/Share
|
|
May 28
2021
|
Maykin Ho Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+25.35%
|
-
|
|
May 28
2021
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+1.45%
|
-
|
|
May 28
2021
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+23.35%
|
-
|
|
May 28
2021
|
Paul J Clancy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+25.35%
|
-
|